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Abstract
Aquated cisplatin was added to half-generation PAMAM dendrimers and the resultant complexes were purified by centrifuge. The drug-dendrimer complexes were then characterised by 1-D and diffusion 1 H NMR y and ICP-AES. The amount of drug bound was found to increase in proportion with dendrimer size: G3.5, 22 cis-{Pt(NH 3 ) 2 }molecules per dendrimer; G4.5, 37; G5.5, 54; and G6.5, 94, which represent only a fraction of the available binding sites on each dendrimer (68, 58, 42 and 37%, respectively). Drug release studies
showed that some drug remains bound to the dendrimer even after prolonged incubation with 5'GMP at temperatures of 60 o C for over a week (percentage of drug released 18, 30, 35 and 63%, respectively). Attachment of the drug was found to decrease the radius of the dendrimers. Finally, the effect of the dendrimer on drug cytotoxicity was determined using in vitro assays with the A2780, A2780cis and A2780cp ovarian cancer cell lines. The free dendrimers display no cytotoxicity whilst the drug-dendrimer complexes showed moderate activity. In vivo activity was examined using an A2780 tumour xenograft. Cisplatin, at its maximum tolerated dose of 6 mg/kg, reduced tumour size by 33% compared to an untreated control group. The G6.5 cisplatin-dendrimer complex was administered at two doses (6 and 8 mg/kg equivalent of cisplatin). Both were well tolerated by the mice. The lower dose displayed comparable activity to cisplatin with a tumour volume reduction of 32%, but the higher dose was significantly more active than free cisplatin with a tumour reduction of 45%.
Introduction
Cisplatin, cis-diamminedichloridoplatinum(II), has been used for the treatment of human cancers for the last 30 years ( Fig. 1 ) [1] [2] . Whilst it is highly effective for testicular cancer its high dose limiting side-effects and the ability of some cancer types, like ovarian and lung, to develop resistance to the drug, greatly limit its use [1] . Five other platinum drugs, carboplatin, oxaliplatin, lobaplatin, heptaplatin and nedaplatin are also used in varying regions with limited success [1] . Whilst new drugs continue to be developed, they all contain structural similarities with cisplatin, and as such exhibit severe dose limiting side-effects [1] .
As such, over the last decade there has been a shift in focus from drug design to drug delivery [1] .
The purpose of a delivery vehicle is to increase the specificity of drug for tumours compared with normal cells. For solid tumours, nanosized delivery vehicles can passively target cancers through use of the enhanced permeability and retention (EPR) effect. The EPR effect arises due to differences between the blood vessels surrounding the tumours and those of normal tissues [3] . The blood vessels in tumours are irregular in shape, dilated, leaky or defective and the endothelial cells in the vessels are poorly aligned [4] . The defects within the vasculature results in blood plasma components such as macromolecules, nano-and lipid particles, entering the tumour tissue more effectively [4] . The increased permeability of tumours allows the passage of larger molecules into the cells than would normally occur [5] . The enhanced permeability can therefore be exploited by nanosized vehicles as these would pass through into the tumour but not into healthy tissue, thus increasing the selectivity of these drugs [6] .
The EPR effect also allows drugs to accumulate in the tumour site due to poor lymphatic drainage [5] .
One family of potential delivery vehicles are dendrimers which are monodispersed polymers, spherical in shape and which are be easily functionalised with a range of biologically relevant groups (NH 2 or COOH), making them ideal for drug delivery applications [7] [8] [9] . The number of surface groups on a dendrimer is dependent on the number of cascading branches;
dendrimer sizes are usually expressed in terms of the number of cascades or generations.
Hence a dendrimer with two cascading branches is a generation 2 (G2) dendrimer [8] .
Dendrimers with only half a full terminal cascading branch are called half generation (e.g.
G2.5) dendrimers [8] . Poly(amidoamine) or PAMAM dendrimers consist of polyamide branches stemming from a central ammine or diaminoalkane core (see Fig. 1 [10] [11] [12] [13] [14] , whereas the half generation dendrimers have multiple anionic charges which are ideal for cationic drugs or for reversible coordination to platinum complexes [15] . PAMAM dendrimers of generations 1 to 10 are nanometre in diameter, and thus, ideal for targeting tumours through the EPR effect.
Previously dendrimers have been examined sporadically as delivery vehicles for several different types of platinum drugs and complexes [15] [16] [17] [18] [19] [20] [21] [22] . These dendrimers have included PAMAM, polyglycerol [22] , poly(propyleneimine) [23] , and thiol-yne derived [21] dendrimers with the active components of both cisplatin [17] and oxaliplatin [16] and a novel DNA intercalating platinum complex [15] . In some cases the platinum drugs are attached non-reversibly to the dendrimer through coordination to the amine groups, but in most cases the drugs were attached either by electrostatic attraction [15] , or through reversible but direct coordination of the platinum atom to the terminal carboxylate groups [16] [17] . In one case a G1 poly(propyleneimine) dendrimer was used as the central bridging ligand in a tetranuclear platinum complex, instead of as a drug delivery vehicle [23] . Whilst the resultant complex was able to bind guanosine, it demonstrated little cytotoxicity. We wish to more comprehensively study the family of PAMAM dendrimers as potential EPR passively targeted drug delivery vehicles for platinum-based drugs, thereby determining the optimal dendrimer size/generation and drug combination for in-depth preclinical evaluation.
In this first study we have completed a systematic study of four anionic half-generation PAMAM dendrimers (G3. Pt spectra were recorded using 80,000 scans over a spectral width of 75,000 Hz and externally referenced to K 2 PtCl 4 at -1631 ppm [24] .
Diffusion NMR
The diffusion coefficients of the free dendrimers and the drug-dendrimer complexes were determined using a standard Bruker diffusion ordered spectroscopy (DOSY) pulse sequence.
Spectra were obtained using a Δ of 100 ms, a δ of 5 ms with 32 scans and a relaxation delay of 2 s. The diameters of the dendrimers were determined using the Stokes-Einstein equation: 
ICP-AES
Analysis was carried out on a Thermo Electron X-Series II quadrupole ICP-AES with a Cetac 
Cisplatin aquation
Cisplatin was fully dissolved in water, wrapped in foil to prevent degradation by light before being stirring for 24 h with AgNO 3 (2 mol. equiv.). The resultant AgCl precipitate was removed by filtration through a 0.2 µm nylon filter and the filtrate rotary evaporated to dryness.
Synthesis of dendrimer-drug complexes
Dendrimer in water (0.5-7.9 mM, 100-210 μL) was stirred with bis-aquated cisplatin (32-256 mol. equiv.) overnight in water (10 mL). The solutions were then centrifuged in Vivaspin™ columns with a 5 kDa molecular weight cut-off membrane for 40 min at 3500 rpm. The drugdendrimer complexes were collected separately into small sample vials and placed in a fume cupboard to evaporate the remaining water to yield a brown solid or instead diluted in column were collected then evaporated to dryness and the residue reconstituted in water (10.00 mL) for analysis by ICP-AES.
Monitoring drug release through binding to guanosine monophosphate
The drug-dendrimer complexes were dissolved in D 2 O (520 μL) and placed in an NMR tube.
5′-guanosine monophosphate in D 2 O (2 mol. equiv. to total Pt content) was added and the solution heated for periods up to 1 week at temperatures up to 60 o C, and the 1 H NMR spectra recorded at intervals.
In vitro growth inhibition assays
The A2780, A2780cis and A2780cp ovarian cancer lines were grown in RPMI media 
In vivo tumour growth inhibition
The human ovarian tumour cell line A2780 was used. These form well vascularised tumours all tumours of equal size; however, the growth rate is consistent regardless of starting size provided it is greater than 5 mm.
Results and discussion

Synthesis and characterisation of drug-dendrimer complexes
In order to attach the active component of cisplatin to the dendrimers, cisplatin needs to be aquated so that it can form reversible coordinate bonds to the carboxylate groups of the dendrimers (Fig. 1) . Cisplatin can either be mono-aquated and form a single bond with the dendrimer or bis-aquated and form two bonds. We decided to use bis-aquated cisplatin as we hypothesised that this would increase the probability of platinum binding to the dendrimer and result in maximum retention of drug.
Each different sized dendrimer was combined in unbuffered water with four equivalents (to the number of dendrimer surface groups) of triethylamine (TEA) and a half equivalent of bisaquated cisplatin (again, to the number of dendrimer surface groups). These solutions were then stirred for 5 h changing them from uncoloured to yellow coloured solutions. Whilst the pKa of the carboxylic acid groups of the dendrimer is around 2, the close packing of so many groups on such a small surface (64-512 carboxylic acid groups) makes complete deprotonation of all the carboxylates difficult. TEA, as a weak base, was added therefore to ensure the maximum number of carboxylate groups were available for coupling to the aquated cisplatin. The TEA as a weak nucleophile, however, can also potentially bind to the aquated cisplatin and in separate experiments of TEA and aquated cisplatin only, significant downfield shifts of the TEA resonances (0.26 ppm for the -CH 2 -group and 0.1 ppm for the -CH 3 group, respectively) indicate this is the case. Therefore, our method of coupling platinum to the dendrimers can form a range of platinum species; mostly dendrimer bound platinum but also TEA bound platinum.
Unbound aquated cisplatin, free TEA and platinum bound TEA were removed by centrifuging the samples on Vivaspin columns with a molecular weight cut off of 5 kDa, leaving the drug-dendrimer complexes in the top of the column (Fig. 1) . The drug-dendrimer complexes are highly soluble in water, although if dried, they are difficult to get back into solution. As such, samples were generally diluted to a known concentration with either H 2 O or D 2 O immediately after centrifuge purification and kept until needed, rather than stored as a solid.
The number of platinum molecules bound to each dendrimer was determined using ICP-AES.
Originally we tried examining the drug-dendrimer complexes directly, but decomposition and deposition of the dendrimer in the machine blocked the ports and gave unreliable results. As such, the Vivaspin centrifuge filtrate (containing unbound aquated cisplatin, and TEA-boundplatinum) was analysed to determine the concentration of unbound platinum, and from this, ppm and a group of much smaller intensity between 5.6 and 6.2 ppm (Fig. 3) . Upon centrifuging in a Vivaspin column the resonances around 5-6 ppm disappear leaving only a group of 9-10 resonances in the aliphatic region. These results indicate that the dendrimers, as supplied by Sigma-Aldrich and Dendritech, come with some lower molecular mass impurities that can be removed by Vivaspin centrifuge. Therefore, all commercial PAMAM dendrimers should be purified first before reaction with platinum drugs.
Addition of bis-aquated cisplatin to each dendrimer induces changes in the dendrimer 1 H NMR spectra (see Fig. 2 ). Five broad resonances are observed between 2.4 and 3.4 ppm, leaving three relatively sharps resonances at 2 and between 3.6 to 3.8 ppm. The size of the free dendrimers and the drug-dendrimer complexes was determined using diffusion NMR (see Table 1 ). The diffusion coefficient of the free dendrimers decreases with increasing dendrimer generation, consistent with larger particle sizes [26] . The dendrimers range in diameter from 2.7 to 5.9 nm, which are significantly less than those previously reported [15] .
Full generation PAMAM dendrimers G4-G7, have previously been shown to have diameters of 4-8 nm [27] , and similar to the results reported by Wiwattanapatapee et al [28] , for G3.5 (4.0 nm) and G5.5 (6.7 nm) dendrimers, which are roughly in agreement with our results. In all cases, addition of cis-{Pt(NH 3 ) 2 } results in a decrease in the size of each dendrimer. In their free form, the anionic carboxylate groups of the dendrimers most likely hydrogen bond with one or more shells of water molecules, thus greatly increasing the dendrimers' effective hydrodynamic radius. When platinum binds to the dendrimers they become significantly less charged, and whilst the ammine groups of cis-{Pt(NH 3 ) 2 } can still hydrogen bond with water, they may do so with much less efficiency, which may explain the reduction in dendrimer size upon platinum attachment.
Whilst we used bis-aquated cisplatin, it wasn't possible to determine whether the cis{Pt(NH 3 ) 2 } binds to the dendrimers in a mono-dentate or bi-dentate fashion as no resonances are observed in the 195 Pt NMR. This is presumably due to the incompatible tumbling rate of the drug-dendrimer complex, which has been also been the case for other metal-based supracomplexes of PAMAM dendrimers [15] .
Drug release and DNA binding
To act as drug delivery vehicles it is important that the dendrimers are not only able to couple platinum drugs, but they must also be able to release the drugs so that they can bind to their cellular target, DNA. To do this we have examined platinum release from the dendrimers using 5΄-guanosine monophosphate binding experiments. (Fig. 3 ) [29] . Free cisplatin is known to react with guanosine/DNA in a relatively short time period (t 1/2 = 0.5-4 h) [29] [30] . For our drug-dendrimer complexes the platinum release is significantly slower and in fact never goes to theoretical completion (see Table 1 [18] , and these are likely to also be formed by our aquated cisplatin.
To examine if non-reversible amine binding is a probable explanation of the incomplete drug release from the dendrimer we examined the reaction of aquated cisplatin with 3-(diethylamino)propionate by 1 H NMR which we use as a representative "fragment" of a dendrimer arm (Fig. 4) . This small molecule contains the functional groups of interest in the half-generation PAMAM dendrimers; a terminal carboxylate group separated from a tertiary amine by an ethyl chain. As purchased, the amine of the fragment is protonated. Upon The results indicate that binding of the platinum atom to the tertiary amines in the full dendrimer arms is possible and may explain the incomplete drug release. What is likely to occur when the aquated cisplatin is coupled to the dendrimer is initial binding to a single carboxylate group. Then, over time, it is likely that a 5-membered chelate ring is formed, involving a carboxylate oxygen and a tertiary amine nitrogen. With longer time, the percentage of platinum bound to the amines will increase and there may even be formation of 5-membered rings involving both the amine and amide nitrogen atoms, and some crosslinking of the dendrimer arms.
Our guanosine monophosphate binding results demonstrate that the amount of platinum released is dependent on dendrimer generation; the higher the generation, the more platinum that is released. This may be due to the dense surface of higher generation dendrimers which prevents access of the platinum atom to the internal amine/amide groups, thus ensuring a higher proportion of surface carboxylate attached drug molecules.
The binding of platinum to the dendrimer amine/amide groups is problematic in that it will make synthesis of consistent drug-dendrimer complexes very difficult. If PAMAM dendrimers are used for drug delivery then our results suggest that higher generation dendrimers, >G5 are preferable to lower generation dendrimers <G4. Alternatively, the problem of amine binding might be overcome through the use of different dendrimer structures (i.e. not PAMAM dendrimers) that do not contain competitive binding sites for platinum. Instead, we hypothesise that other commercially available dendrimers could be functionalised with carboxylate groups through simple polyamide or click chemistry, and we plan to investigate this in the future.
In Vitro Cytotoxicity
The cytotoxicity of the free dendrimers and the drug-dendrimer complexes were determined in the human ovarian carcinoma cell line A2780 and its cisplatin-resistant daughter lines, A2780cis and A2780cp. These cell lines were chosen as ovarian tumours are known to easily developed acquired resistance and therefore in a particular need for a new drug delivery system to either increase the administered dose, thereby preventing the development of resistance, or to increase the delivered dose in already resistance tumours.
Anionic half generation dendrimers have previously been shown to be significantly less cytotoxic compared with cationic full generation dendrimers [31] , and our results demonstrated that the free PAMAM dendrimers have no cytotoxicity (IC 50 >100 µM).
Because the release of platinum is so slow from the dendrimers, we incubated the cancer cell lines with drug-dendrimer complexes for time periods between 24 and 96 h. When the assays were conducted with the WST-1 stain in the A2780 and A2780cis lines, it was found the complexes were inactive, with IC 50 values greater than 100 µM in all cases. Conversely, moderate cytotoxicity is observed when the A2780 and A2780cp lines are stained with MTT (Table 2) , which indicates that WST-1 is not a suitable stain for in vitro screening of platinum drugs. Previously we have also shown that Alamar Blue is not a suitable stain for platinum drug screening [32] , and we recommend the continued use of MTT.
All four drug-dendrimer complexes display moderate activity in the A2780 cell line, although they are 2-to 11-fold less active than cisplatin. In the cisplatin-resistant line, all four complexes are significantly less cytotoxic and are not able to overcome resistance in the 
In Vivo Effectiveness
Whilst disappointing, the in vitro results were not surprising as previously Malik et al. [17] found that a PAMAM G3.5 dendrimer with the active component of cisplatin attached was almost inactive in CCRF, COR L23 and B16F10 cells when tested in vitro. Significant activity was only observed in vivo in L1210 murine leukaemia and B16 melanoma bearing mice. In another study, in vitro cytotoxicity was only observed when a platinum-dendrimer complex was incubated with cells for very long periods of time: 75 to 225 h [33] . Therefore our in vitro results do not necessarily imply that the drug-dendrimer complexes developed in this study are not active and different methods for determining cytotoxicity, including in vivo experiments, may be necessary for dendrimer-based delivery systems to be investigated properly.
To this effect, and as only an initial pre-screen until other platinum drugs have been examined with PAMAM dendrimers, we then determined the effectiveness of the cis{Pt(NH 3 ) 2 }-G6.5 complex in vivo using an A2780 tumour xenograft. The G6.5 complex was chosen because with the G5.5 complex, it was most effective at overcoming resistance.
Additionally, it is able to release more cis-{Pt(NH 3 ) 2 } molecules than the other three dendrimers and because its larger size meant it was more likely to be trapped within the tumour vasculature compared with the other drug-dendrimer complexes.
When free cisplatin and the cis-{Pt(NH 3 ) 2 }-G6.5 complex were administered at equimolar doses of 6 mg/kg (based on the number of releasable cisplatin molecules from the G6.5 dendrimer), both demonstrated similar, and statistically significant, effectiveness in delaying tumour growth (Fig. 5) . Conversely, the free G6.5 dendrimer had no effect on tumour growth (data not shown). When administered at a higher dose (8 mg/kg) the drug-dendrimer complex demonstrated similar systemic side-effects, as determined by the relative decrease in the mice's body weight, but was significantly better at delaying tumour growth. Seven days after administration the tumour volumes of the cisplatin and drug-dendrimer complex (6 mg/kg) were 67 and 68%, respectively, of the tumour volume of the untreated control group (P <0.001). The drug-dendrimer complex (8 mg/kg) significantly delayed growth to an even greater extend with a tumour volume of only 55% compared to the control group (P <0.001).
The tumour doubling times were: control group 3.17 ± 0.15 days; cisplatin, 4.87 ± 0.14 days; drug-dendrimer 6 mg/kg 5.2 ± 0.35 days; and drug-dendrimer 8 mg/kg, 6.32 ± 0.37 days.
These results further support our hypothesis that in vitro assays are not a suitable screen alone for platinum drug-nanoparticle delivery vehicle systems and in vivo experiments are required to determine their effectiveness properly.
Conclusions
In this paper we conducted a systematic examination of half generation anionic PAMAM a. Based on the total "releasable" platinum concentration per mole of dendrimer. b. Defined 4 as the IC 50 value in the resistant line divided by the IC 50 value in the sensitive line; the lower 5 the Rf the better the complex is at overcoming resistance. 
